Christophe Le Tourneau

Christophe Le Tourneau

UNVERIFIED PROFILE

Are you Christophe Le Tourneau?   Register this Author

Register author
Christophe Le Tourneau

Christophe Le Tourneau

Publications by authors named "Christophe Le Tourneau"

Are you Christophe Le Tourneau?   Register this Author

100Publications

4222Reads

40Profile Views

Molecular screening programs in different countries: what we learned and perspectives.

Curr Opin Oncol 2019 Sep;31(5):445-453

Department of Drug Development and Innovation (D3i), Institut Curie.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000561DOI Listing
September 2019

Pembrolizumab for the treatment of cervical cancer.

Expert Opin Biol Ther 2019 Sep 23;19(9):871-877. Epub 2019 Jul 23.

b Department of Drug Development and Innovation (D3i), Institut Curie , Paris & Saint-Cloud , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1646721DOI Listing
September 2019

4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.

Cancer Immunol Immunother 2019 08 15;68(8):1391-1400. Epub 2019 Jul 15.

Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras avenue, 11522, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02364-2DOI Listing
August 2019

ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials.

Comput Biol Med 2019 Aug 24;111:103339. Epub 2019 Jun 24.

INSERMU1153, Statistic and Epidemiologic Research Center Sorbonne Paris Cité (CRESS), ECSTRRA Team, Saint-Louis Hospital, 75010, Paris, France; Paris Diderot University, Paris, France; SBIM, Saint-Louis Hospital, APHP, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiomed.2019.103339DOI Listing
August 2019

Molecular profiling in precision medicine oncology.

Nat Med 2019 05;25(5):711-712

Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41591-019-0442-2
Publisher Site
http://dx.doi.org/10.1038/s41591-019-0442-2DOI Listing
May 2019

Imputability of Adverse Events to Anticancer Drugs.

N Engl J Med 2019 05;380(19):1873-1874

Institut Curie, Paris, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1900053DOI Listing
May 2019

Hyperprogression under Immunotherapy.

Int J Mol Sci 2019 May 30;20(11). Epub 2019 May 30.

Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20112674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600249PMC
May 2019

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.

Front Oncol 2019 13;9:74. Epub 2019 Feb 13.

Department of Drug Development & Innovation (D3i), Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381014PMC
February 2019

Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?

Chin Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France; INSERM U900 Research unit, Saint-Cloud, France; Paris-Saclay University, Saint-Aubin, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2019.01.08DOI Listing
February 2019

Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny.

Cell Rep 2018 Oct;25(3):811-821.e5

Department of Medical Oncology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris, Sorbonnes-Universités, University Pierre and Marie Curie, Paris, France; Department of Hematology and Medical Oncology, CHRU Strasbourg, Hôpital Hautepierre, Strasbourg, France; Institut Génomique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247183149
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2018.09.047DOI Listing
October 2018

Precision medicine in oncology: what is it exactly and where are we?

Per Med 2018 09 27;15(5):351-353. Epub 2018 Sep 27.

Pharmacogenomics Unit, Institute Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pme-2018-0036DOI Listing
September 2018

Patterns of Response and Progression to Immunotherapy.

Am Soc Clin Oncol Educ Book 2018 May;38:169-178

From the Department of Drug Development and Innovation, Institut Curie, Paris and Saint-Cloud, France; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Melanoma Institute Australia, North Sydney, NSW, Australia; INSERM U900 Research Unit, Saint-Cloud, France; Versailles Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200643DOI Listing
May 2018

Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.

Cancer Treat Rev 2018 Apr 1;65:54-64. Epub 2018 Mar 1.

Hôpital Européen Georges Pompidou, APHP, Department of Pathology, APHP, Paris Descartes Sorbonne Paris-Cité University, Paris, France; INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.02.008DOI Listing
April 2018

Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine.

Sci Eng Ethics 2018 02 9;24(1):307-322. Epub 2017 Mar 9.

Medical Ethics and Legal Medicine Laboratory EA4569, Paris Descartes University, Centre Universitaire des Saints-Pères, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11948-017-9880-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799317PMC
February 2018

Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?

Chin Clin Oncol 2018 02 6;7(1). Epub 2017 Nov 6.

Institute Curie, PSL Research University, Department of Medical Oncology, Paris, France; INSERM U900 Research Unit, Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2017.10.08DOI Listing
February 2018

Precision medicine strategies in oncology: mixed approaches to matched therapies.

Future Oncol 2018 01 11;14(2):105-109. Epub 2017 Dec 11.

Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0524DOI Listing
January 2018

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

J Clin Oncol 2017 Dec 24;35(36):4050-4056. Epub 2017 Aug 24.

Chiun Hsu, National Taiwan University Hospital, Graduate Institute of Oncology, National Taiwan University College of Medicine, and National Taiwan University Cancer Center, Taipei, Taiwan, Republic of China; Se-Hoon Lee, Seoul National University Hospital, Seoul, South Korea; Samuel Ejadi, Virginia G. Piper Cancer Center, Scottsdale, AZ; Roger B. Cohen, University of Pennsylvania, Philadelphia, PA; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Alain Algazi, University of California, San Francisco, San Francisco, CA; Sanatan Saraf, Pradeep Thanigaimani, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ; Caroline Even, Gustave Roussy, Villejuif; Christophe Le Tourneau, Institut Curie, Paris; Christophe Le Tourneau, INSERM U900 Research Unit, Saint-Cloud, France; Emilie M.J. van Brummelen, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Aaron R. Hansen, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.3675DOI Listing
December 2017

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

J Clin Oncol 2017 Dec 2;35(36):4035-4041. Epub 2017 Nov 2.

Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.5471DOI Listing
December 2017

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Eur J Cancer 2017 09 22;83:185-193. Epub 2017 Jul 22.

Drug Development Department (DITEP), Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.016DOI Listing
September 2017

Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing: A Solution for Transferring Integrated Pangenomic Studies into Routine Practice?

J Mol Diagn 2017 09;19(5):776-787

Institut Cochin, INSERMU1016, Centre National de la Recherche Scientifique UMR_8104, Paris, France; Department of Endocrinology, Reference Center for Rare Adrenal Diseases, Reference Center for Rare Adrenal Cancer Network COMETE, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15251578173026
Publisher Site
http://dx.doi.org/10.1016/j.jmoldx.2017.06.005DOI Listing
September 2017

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

Oncotarget 2017 08 4;8(31):51830-51839. Epub 2017 Mar 4.

Bergonié Institute, Clinical and Epidemiological Research Unit & INSERM U897 & Data Center for Cancer Clinical Trials, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584293PMC
August 2017

The SHIVA01 trial: what have we learned?

Pharmacogenomics 2017 06 8;18(9):831-834. Epub 2017 Jun 8.

Pharmacogenomics Unit, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2017-0062DOI Listing
June 2017

Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.

Ther Adv Med Oncol 2017 Jun 8;9(6):431-439. Epub 2017 May 8.

Department of Medical Oncology, Institut Curie, INSERM U900 Research unit, 35 rue Dailly, 92210 Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017708742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455883PMC
June 2017

Patient-reported tolerability of adverse events in phase 1 trials.

ESMO Open 2017 23;2(2):e000148. Epub 2017 Jun 23.

Drug Development department (DITEP), Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519806PMC
June 2017

[Current events in immunotherapy for upper aerodigestive tract cancer].

Ann Pathol 2017 Feb 19;37(1):79-89. Epub 2017 Jan 19.

Service d'anatomie pathologique, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France; Inserm U 970, équipe 10, PARCC, faculté Paris Descartes, 75015 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annpat.2016.12.013DOI Listing
February 2017

[Cell cycle inhibitors in endocrine receptor positive breast cancer].

Bull Cancer 2017 Feb 23;104(2):114-122. Epub 2017 Jan 23.

Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.12.005DOI Listing
February 2017

Targeted therapies: What have we learned from SHIVA?

Nat Rev Clin Oncol 2016 12 11;13(12):719-720. Epub 2016 Oct 11.

Center for Personalized Cancer Therapy and the Division of Haematology and Oncology, UCSD Moores Cancer Center, 3855 Health Sciences Dr # 987, La Jolla, California 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.164DOI Listing
December 2016

Combinations of targeted therapies in human cancers.

Aging (Albany NY) 2016 10;8(10):2258-2259

Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.101085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115885PMC
October 2016

Cytological features of NUT midline carcinoma arising in sino-nasal tract and parotid gland: Report of two new cases and review of the literature.

Diagn Cytopathol 2016 Sep 24;44(9):753-6. Epub 2016 Jun 24.

Department of Pathology, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.23506DOI Listing
September 2016

Antibody drug conjugates: the future of chemotherapy?

Curr Opin Oncol 2016 09;28(5):429-36

aDepartment of Medical Oncology, Institut Curie, Paris & Saint-Cloud bEA7285, Versailles-Saint-Quentin-en-Yvelines University, Versailles, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000310DOI Listing
September 2016

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.

J Natl Cancer Inst 2016 Apr 23;108(4). Epub 2015 Nov 23.

Affiliations of authors:Department of Medical Oncology, Institut Curie , Paris & Saint-Cloud , France (CLT, MK, MA); EA7285 Versailles-St-Quentin-en-Yvelines University , France (CLT, RR); Investigational Cancer Therapeutics, M. D. Anderson Cancer Center , Houston, TX (AMT); Drug Development Program, Department of Medical Oncology and Hematology, Princess Margaret Hospital , Toronto , Canada (PB); Department of Genetics, Institut Curie , Paris , France (GP, CC, ER, IB); Department of Pathology, Institut Curie , Paris , France (AVS); Institut Curie / INSERM U900 , Paris , France (NS, XP); Department of Surgery, Institut Curie , Paris & Saint-Cloud , France (RR); Institut Curie, INSERM U830 , Paris , France (OD); EA7331, University of Paris-Descartes , Paris , France (IB).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830395PMC
April 2016

Precision medicine: lessons learned from the SHIVA trial - Authors' reply.

Lancet Oncol 2015 Dec;16(16):e581-2

Institut Curie, 92210 Saint-Cloud, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00455-6DOI Listing
December 2015

Design and statistical principles of the SHIVA trial.

Chin Clin Oncol 2015 Sep;4(3):32

Unité INSERM, Institut Curie, Mines ParisTech U900, Paris, France; Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris and Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.02.02DOI Listing
September 2015

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Clin Cancer Res 2015 Jun 11;21(12):2753-62. Epub 2015 Mar 11.

Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2141DOI Listing
June 2015

Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.

Oncologist 2015 Jun 11;20(6):653-9. Epub 2015 May 11.

Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Division of Hematology and Oncology Toxicology, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France; INSERM U900, Institut Curie, Paris, France; Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571794PMC
June 2015

Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials.

Crit Rev Oncol Hematol 2015 May 3;94(2):189-200. Epub 2015 Jan 3.

EMR UCBL/HCL 3738, Faculté de médecine Lyon-Sud, Université Claude Bernard Lyon 1, Lyon, France; Oncologie Médicale, Centre d'Investigation des Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL), Groupement Hospitalier Sud, Institut de Cancérologie des Hospices, Civils de Lyon (IC-HCL), Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2014.12.014DOI Listing
May 2015

Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.

Mol Oncol 2015 Apr 26;9(4):783-90. Epub 2014 Dec 26.

Circulating Cancer Biomarkers Lab, SiRIC, Translational Research Department, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France; University Paris Descartes, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.12.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528781PMC
April 2015

[Nanoparticles and radiation therapy].

Bull Cancer 2015 Jan 9;102(1):83-91. Epub 2015 Jan 9.

Centre Lacassagne, département d'oncologie radiothérapie, Cyclotron médical, 33, avenue Valembrose, 06100 Nice, France; Centre Lacassagne, département d'oncopharmacologie UE3836, 33, avenue Valembrose, 06100 Nice, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2014.10.002DOI Listing
January 2015

Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.

Bioinformatics 2014 Dec 12;30(24):3443-50. Epub 2014 Jul 12.

Inserm, U900, Bioinformatics, Biostatistics, Epidemiology and Computational Systems Biology of Cancer, Institut Curie, Centre de Recherche, 26 rue d'Ulm, Paris 75248, Mines ParisTech, Fontainebleau 77300, Inserm, U830, Genetics and Biology of Cancers, Paris 75248, France, Institut de Pathologie et de Génétique, Gosselies 6041, Belgium, Clinical Research Department, Department of Medical Oncology, Plateforme de Génomique, Département de recherche translationnelle, Centre de recherche, Next-generation sequencing platform, Institut Curie, CNRS, UMR144, Subcellular Structure and cellular Dynamics, Paris 75248, France and OncoDNA, Gosselies 6041, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btu436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253825PMC
December 2014

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Eur J Cancer 2014 Aug 10;50(12):2050-6. Epub 2014 Jun 10.

Gustave Roussy Cancer Campus, DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Villejuif, France; Université Paris-Sud XI, Orsay, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.04.030DOI Listing
August 2014

The spectrum of clinical trials aiming at personalizing medicine.

Chin Clin Oncol 2014 Jun;3(2):13

Institut Curie, Unité INSERM/Institut Curie U900, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2014.05.02DOI Listing
June 2014

[Recurrence of upper aerodigestive tract tumors].

Bull Cancer 2014 May;101(5):511-20

Institut Curie, Département de recherche clinique, 26 rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2014.1970DOI Listing
May 2014

Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.

Eur J Cancer 2014 Feb 17;50(3):638-48. Epub 2013 Nov 17.

Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France; Institut Curie/INSERM U900, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.10.016DOI Listing
February 2014

Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.

J Clin Oncol 2014 Jan 2;32(3):260-3. Epub 2013 Dec 2.

Institut Curie and Institut National de la Sante et de la Recherche Medicale U900, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.5518DOI Listing
January 2014

A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.

Eur J Cancer 2013 Jul 27;49(10):2392-402. Epub 2013 Mar 27.

Biostatistics department, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.02.028DOI Listing
July 2013

Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey.

Acta Ophthalmol 2013 May 4;91(3):195-206. Epub 2012 Apr 4.

Eye Pathology Institute, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1755-3768.2012.02402.x
Publisher Site
http://dx.doi.org/10.1111/j.1755-3768.2012.02402.xDOI Listing
May 2013

A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.

Am J Clin Oncol 2012 Jun;35(3):255-60

Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e31820dbdccDOI Listing
June 2012

[Renal insufficiency and breast cancer].

Bull Cancer 2012 Mar;99(3):309-15

Institut Curie, département oncologie médicale, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1478DOI Listing
March 2012

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland.

Br J Ophthalmol 2011 Nov 22;95(11):1483-9. Epub 2010 Dec 22.

Département d'Oncologie Médicale - Unité d'Investigation Clinique, Institut Curie, 26, rue d'Ulm - 75248 Paris Cedex 05, France.

View Article

Download full-text PDF

Source
http://bjo.bmj.com/cgi/doi/10.1136/bjo.2010.192351
Publisher Site
http://dx.doi.org/10.1136/bjo.2010.192351DOI Listing
November 2011

[Targeting the RAS signalling pathway in cancer].

Bull Cancer 2011 Oct;98(9):1019-28

CHU de Besançon, département d'oncologie médicale, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1380DOI Listing
October 2011

[Prevention strategies for brain metastases from HER2-positive breast cancer].

Bull Cancer 2011 Apr;98(4):445-9

Institut Curie, département d’oncologie médicale, unité d’investigations cliniques, 25, rue d’Ulm,75248 Paris Cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1345DOI Listing
April 2011

Development of anti-cancer drugs.

Discov Med 2010 Oct;10(53):355-62

Clinical Trial Unit, Department of Medical Oncology, Institut Curie, Paris 75248, France.

View Article

Download full-text PDF

Source
October 2010

Molecular targeted therapies in all histologies of head and neck cancers: an update.

Curr Opin Oncol 2010 May;22(3):212-20

Drug Development Program, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e328338001fDOI Listing
May 2010

Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.

J Clin Oncol 2010 Mar 1;28(8):1401-7. Epub 2010 Feb 1.

Division of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.25.9606DOI Listing
March 2010

Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.

J Clin Oncol 2009 Dec 5;27(35):5965-71. Epub 2009 Oct 5.

Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.22.3685
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.22.3685DOI Listing
December 2009